Anavex Life Sciences (AVXL) Research & Development (2016 - 2025)

Anavex Life Sciences (AVXL) has 10 years of Research & Development data on file, last reported at $4.7 million in Q4 2025.

• For the quarter ending Q4 2025, Research & Development fell 55.43% year-over-year to $4.7 million; the trailing twelve-month figure through Dec 2025 stood at $31.8 million (down 27.06% YoY), and the FY2025 full-year result was $37.6 million, down 10.15% from the prior year.
• Research & Development declined to $4.7 million in Q4 2025, from $7.3 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $12.1 million in Q4 2022 to a low of $4.7 million in Q4 2025.
• A 5-year average of $9.5 million and a median of $9.8 million in 2024 frame the typical range for Research & Development.
• Across the five-year window, Research & Development soared 53.53% in 2021 and plunged 55.43% in 2025, its largest moves.
• Tracing AVXL's Research & Development over 5 years: stood at $8.7 million in 2021, then soared by 39.4% to $12.1 million in 2022, then dropped by 28.04% to $8.7 million in 2023, then grew by 20.29% to $10.4 million in 2024, then sank by 55.43% to $4.7 million in 2025.
• Business Quant data shows AVXL's Research & Development at $4.7 million in Q4 2025, $7.3 million in Q3 2025, and $10.0 million in Q2 2025.